SCHEMBL32659771

SCHEMBL32659771

CNc1ncnc2c1c(-c1cccc(-c3ccccc3)c1)nn2CC(C)(C)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 6/20 0.50
▸ PIK3CB P42338 4/20 0.50
▸ PIK3CG P48736 4/20 0.50
▸ PRKDC P78527 4/20 0.45
▸ PIK3CA P42336 3/20 0.45
▸ VCP P55072 4/20 0.43
▸ PRKD3 O94806 1/20 0.42
▸ PSMC4 P43686 1/20 0.41
▸ SRC P12931 3/20 0.41
▸ EGFR P00533 1/20 0.41
▸ FYN P06241 2/20 0.39
▸ RET P07949 1/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23630571 1.00 PIK3CD (0.50) PIK3CDPIK3CBPIK3CGPRKDCPIK3CA
SCHEMBL23630577 0.92 VCP (0.48) PIK3CDPIK3CBPIK3CGVCPPRKD3
SCHEMBL32659768 0.92 VCP (0.48) PIK3CDPIK3CBPIK3CGVCPPRKD3
SCHEMBL32659750 0.87 PIK3CD (0.53) PIK3CDPIK3CBPIK3CGPRKDCPIK3CA
SCHEMBL23630566 0.87 PIK3CD (0.53) PIK3CDPIK3CBPIK3CGPRKDCPIK3CA
SCHEMBL23630535 0.86 PIK3CD (0.39) PIK3CDPIK3CBPIK3CGPRKDCPIK3CA
SCHEMBL32659777 0.86 PIK3CD (0.39) PIK3CDPIK3CBPIK3CGPRKDCPIK3CA
SCHEMBL23630581 0.79 SRC (0.53) PIK3CDPIK3CBPIK3CGPRKDCPIK3CA
SCHEMBL32659753 0.79 SRC (0.53) PIK3CDPIK3CBPIK3CGPRKDCPIK3CA
SCHEMBL23630564 0.76 PRKD3 (0.61) PRKD3SRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522606-B2 Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy UNIVERSITY OF WASHINGTON (US) 2026-01-13 — — US claimed
Send feedback